(VIANEWS) – The Market ended the session with ADOCIA (ADOC.PA) jumping 12.02% to €9.14 on Thursday, after two sequential sessions in a row of gains. CAC 40 fell 1.03% to €7,530.72, after two successive sessions in a row of losses, on what was an all-around negative trend exchanging session today.
ADOCIA’s last close was €8.16, 49.5% under its 52-week high of €16.16.
About ADOCIA
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-1.9.
Revenue Growth
Year-on-year quarterly revenue growth declined by 62.6%, now sitting on 10.84M for the twelve trailing months.
More news about ADOCIA (ADOC.PA).
